Companies › Sequence LifeScience
6 active drug programs in 10 registered trials: 10 Phase 4; Metabolic and endocrine, Immunology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Activate™ Matrix Acellular matrix product for wound healing | – | Phase 4 | Diabetic Foot Ulcer; Skin Ulcer | Jul 2027 |
| AmnioDefend™ FT Matrix Acellular matrix product for wound healing | – | Phase 4 | Diabetic Foot Ulcer; Skin Ulcer | Jul 2027 |
| Enclose™ TL Matrix Acellular tissue-derived matrix scaffold | – | Phase 4 | Diabetic Foot Ulcer | Jul 2027 |
| Palisade™ DM Matrix Acellular matrix product for wound healing | – | Phase 4 | Diabetic Foot Ulcer; Skin Ulcer | Jul 2027 |
| Sentry™ SL Matrix Acellular matrix product for wound healing | – | Phase 4 | Diabetic Foot Ulcer; Skin Ulcer | Jul 2027 |
| Shelter™ DM Matrix Acellular dermal matrix for diabetic foot ulcer wound healing | – | Phase 4 | Diabetic Foot Ulcer | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07086443 | Activate™ Matrix | Phase 4 | Diabetic Foot Ulcer | Metabolic and endocrine | Jul 2027 |
| NCT07086443 | AmnioDefend™ FT Matrix | Phase 4 | Diabetic Foot Ulcer | Metabolic and endocrine | Jul 2027 |
| NCT07086443 | Palisade™ DM Matrix | Phase 4 | Diabetic Foot Ulcer | Metabolic and endocrine | Jul 2027 |
| NCT07086443 | Enclose™ TL Matrix | Phase 4 | Diabetic Foot Ulcer | Metabolic and endocrine | Jul 2027 |
| NCT07086443 | Sentry™ SL Matrix | Phase 4 | Diabetic Foot Ulcer | Metabolic and endocrine | Jul 2027 |
| NCT07086443 | Shelter™ DM Matrix | Phase 4 | Diabetic Foot Ulcer | Metabolic and endocrine | Jul 2027 |
| NCT07665268 | Activate™ Matrix | Phase 4 | Skin Ulcer | Immunology | Jan 2028 |
| NCT07665268 | AmnioDefend™ FT Matrix | Phase 4 | Skin Ulcer | Immunology | Jan 2028 |
| NCT07665268 | Palisade™ DM Matrix | Phase 4 | Skin Ulcer | Immunology | Jan 2028 |
| NCT07665268 | Sentry™ SL Matrix | Phase 4 | Skin Ulcer | Immunology | Jan 2028 |
No annotated target.
–
Applied Biologics Tiger Biosciences BioLab Holdings Yong Zhao, MD, PhD Biocomposites
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.